| Item # | Length | Source of Standard | Year Implemented | Version Implemented | Year Retired | Version Retired |
|---|---|---|---|---|---|---|
| 480 | 1 | NAACCR |
Code that best describes how morphology was originally coded. If later converted, this field shows the original codes used. An update or new Morphology Coding System code incorporates all previous coding updates.
Codes
| 1 | ICD-O, First Edition |
| 2 | ICD-O, 1986 Field Trial |
| 3 | ICD-O, 1988 Field Trial |
| 4 | ICD-O, Second Edition |
| 5 | ICD-O, Second Edition, plus REAL lymphoma codes effective 1/1/1995 |
| 6 | ICD-O, Second Edition, plus FAB codes effective 1/1/1998 |
| 7 | ICD-O, Third Edition |
| 8 | ICD-O, Third Edition, plus 2008 WHO hematopoietic/lymphoid new terms used for conditions diagnosed 1/1/2010\* |
| 9 | Other |
| A | ICD-O, Third Edition, plus WHO new terms used for conditions, effective 1/1/2018\*\* |
| B | ICD-O 3.2, effective 1/1/2021 |
| C | ICD-O-3.2, plus, WHO new terms used for conditions, effective 1/1/2022\*\*\* |
| D | ICD-O-3.2, plus, WHO new terms used for conditions, effective 1/1/2023\*\*\* |
| E | ICD-O-3.2, plus, WHO new terms used for conditions, effective 1/1/2024\*\*\*\* |
Notes:
*These changes were based on the terms of the World Health Organization’s (WHO) fourth edition of the following publications:
For details including the list of terms included, here is the link to the NAACCR ICD-O-3 Implementation Guidelines document, effective for 2014 cases: <https://20tqtx36s1la18rvn82wcmpn-wpengine.netdna-ssl.com/wp-content/uploads/2016/11/ICD-O-3-Implementation-Guide-FINAL.pdf>.
**These changes are based on the terms of the World Health Organization’s (WHO) fourth edition of the following publications:
For details including the list of terms included, here is the link to the NAACCR ICD-O-3 Implementation Guidelines document, effective for 2018 cases: <https://20tqtx36s1la18rvn82wcmpn-wpengine.netdna-ssl.com/wp-content/uploads/2018/01/Updated-Jan-10-2018-ICD-O-3-Guidelines-v2.pdf>.
*** These changes are based on the terms of the World Health Organization’s (WHO) fifth edition of the following publications:
****These changes are based on the terms of the World Health Organization’s (WHO) fifth edition of the following publication:
WHO Classification of Tumors of the Urinary and Male Genital Organs 5th Ed (2022).
For details including the list of terms included, refer to the link to the NAACCR ICD-O-3 Implementation Guidelines document, effective for 2022 cases: TBD.